The impact of diabetes mellitus on survival after myocardial infarction: Can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study

Diabetologia

Volumn 43, Issue 2, 2000, Pages 218-226

  Lowel H ^a   Koenig, W ^b   Engel, S ^c   Hormann A ^a   Keil, U ^d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

28 Day mortality; Acute myocardial infarction; Diabetes mellitus; Long term survival; Population based register; Secondary prevention

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART VENTRICLE FUNCTION; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033998816     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050032     Document Type: Article

References (47)

1. 1. Kannel W-B, McGee D-I (1979) Diabetes and cardiovascular disease. The Framigham Study. J Am Med Assoc 241: 2035-2038
2. 2. Koskinen P, Manttari M, Manninen J, Heinonen O-P, Frick MHS (1992) Coronary heart disease incidence in NIDDM patients in the Helsinki Heart study. Diabetes Care 15: 820-825
3. 3. Stamler J, Vaccaro O, Neaton J, Wentworth D (1993) Diabetes, other risk factors, and 12-yr. cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-449
4. 4. Folsom A-R, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt J-H (1997) A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. Diabetes Care 20: 935-942
5. 5. Löwel H, Stieber J, Koenig W, et al (1999) The diabetes-related risk of MI in a Southern German population: results of the MONICA Augsburg studies 1985-1994 (in German). Diabetes und Stoffwechsel 8: 11-21
6. 6. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F (1997) Diabetes as a risk factor for MI: population and gender perspectives. J Intern Med 241: 485-492
7. 7. Pyörälä K, Laakso M, Uusitupa M (1987) Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 3: 463-524
8. 8. Standl E, Balletshofer B, Dahl B et al (1996) Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project. Diabetologia 39: 1540-1545
9. 9. Hanefeld M, Fischer S, Julius U et al, The DIS group (1996) Risk factors for MI and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39: 1577-1583
10. 10. Meigs J-B, Singer D-E, Sullivan L-M et al (1997) Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): The NIDDM Patient Outcomes Research Team. Am J Med 102: 38-47
11. 11. Haffner S-M, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease subjects with type 2 diabetes and in non-diabetic subjects with and without prior MI. N Engl J Med 339: 229-234
12. 12. Bradley R-F, Bryfogie J-W (1956) Survival of diabetic patients after MI. Am J Med 20: 207-216
13. 13. Ulvenstam G, Aberg A, Bergstrand R et al (1995) Long-term prognosis after MI in men with diabetes. Diabetes 34: 787-792
14. 14. Abott R-D, Donahue R-P, Kannel W-B, Wilson P-W-F (1988) The impact of diabetes on survival following MI in men vs women. JAMA 260: 3456-3460
15. 15. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S (1991) In-hospital and 1-year mortality in 1524 women after MI: comparison with 4315 men. Circulation 83: 484-491
16. 16. Karlson W, Herlitz J, Hjalmarson A (1993) Prognosis of acute MI in diabetic and non-diabetic patients. Diabet Med 10: 449-454
17. 17. Abbud Z-A, Shindler D-M, Wilson A-C, Kostis L-B, for the MI Data Acquisition System Study Group (1995) Effect of diabetes mellitus on short-and long-term mortality rates of patients with acute MI: A statewide study. Am Heart J 130: 51-58
18. 18. Behar S, Boyko V, Reicher-Reiss H, Goldbourt U, for the SPRINT Study Group (1997) Ten-year survival after acute MI: Comparison of patients with and without diabetes. Am Heart J 133: 290-296
19. 19. Chun B-Y, Dobson A-J, Heller R-F (1997) The impact of Diabetes on survival among patients with first MI. Diabetes Care 20: 704-708
20. 20. Miettinen H, Lehto S, Solomaa V, et al (1998) Impact of diabetes on mortality after the first MI. Diabetes Care 21: 69-75
21. 21. Zuanetti G, Latini R, Maggioni A-P, Santoro L, Franzosi M-G on behalf of GISSI-2-Investigators (1993) Influence of diabetes on mortality in acute MI: data from the GISSI-2 study. J Am Coll Cardiol 22: 1788-1794
22. 22. Barbash G-I, White H-D, Modan M, Ven de Werf F, for the Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial (1993) Significance of diabetes mellitus in patients with MI receiving thrombolytic therapy. J Am Coll Cardiol 22: 707-713
23. 23. Becker R-C, Terrin M, Ross R et al, and the Thrombolysis in MI Investigators (1994) Comparison of clinical outcomes for women and men after acute MI. Ann Intern Med 120: 638-645
24. 24. Mak K-H, Moliterno D-J, Granger C-B et al, for the GUSTO-I Investigators (1997) Influence of diabetes mellitus on clinical outcome in thrombolytic era of acute MI. J Am Coll Cardiol 30: 171-179
25. 25. Koenig W, Löwel H, Lewis M, Hörmann A (1996) Long-term survival after MI: relationship with thrombolysis and discharge medication. Eur Heart J 17: 1199-1206
26. 26. World Health Organization Principal Investigators (prepared by H Tunstall-Pedoe) (1988): The World Health Organziation MONICA Project (Monitoring of Trends and Determinants in Cardiovascular Disease): A major international collaboration. J Clin Epidemiol 34: 105-114
27. 27. The World Health Organzation (1990) MONICA Manual (Revised Edition) Cardiovascular Disease Unit, World Health Organization, Geneva
28. 28. Löwel H, Lewis M, Hörmann A, Keil U (1991) Case finding, data quality aspects, and comparability of MI registers. Results of a Southern German register study. J Clin Epidemiol 44: 249-260
29. 29. Prineas R-J, Crow R-S, Blackburn H (1992) The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. John Wright, Boston, Bristol
30. 30. The Expert Committee on the Diagnosis and Classification of Diabetes mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Diabetes Care 20: 1183-1197
31. 31. The PHREG Procedure (1996) In: SAS/STAT software changes and enhancements. Cary (NC): SAS Institute 807-884
32. 32. The LIFETEST Procedure (1990) In: SAS/STAT User's Guide, version 6, vol. 2, 4th ed. Cary (NC): SAS Institute: 1027-1069
33. 33. Avanzini F, Zuanetti G, Latini R et al, on behalf of the Gruppo Italiano di Studio sulla Sopravvivenza nell'Infarto Miocardico (GISSI) Investigators (1997) Use of beta-blocking agents in secondary prevention after MI: a case for evidence-based medicine? GISSI experience, 1984-1993. Eur Heart J 18: 1447-1456
34. 34. Pankow J-S, McGovern P-G, Sprafka L-M, Jacobs R, Blackburn H (1994) Trends in coded causes of death following definitive MI and the role of competing risks: The Minnesota Heart Survey (MHS). J Clin Epidemiol 47: 1051-1060
35. 35. Orlander P-R, Goff D-C, Morrissey M et al (1994) The relation of diabetes to the severity of acute MI survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes 43: 897-902
36. 36. Hjalmarson A (1997) Effects of betablockade on sudden cardiac death during acute MI and the postinfarction period. Am J Cardiol 80 (9B): 35J-39J
37. 37. American Diabetes Association (1998) Position statement: Aspirin therapy in Diabetes. Diabetes Care 21 [Suppl 1]: 1-3
38. 38. MacDonald T-M, Butler R, Newton R-W, Morris A-D (1998) Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration. Diabet Med 15: 282-289
39. 39. Gottlieb S-S, McCarter R-J, Vogel R-A (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339: 489-497
40. 40. Zuanetti G, Latini R, Maggioni A-P, Franzosi M-G, Santoro L, Tognoni G, for the GISSI-3 Investigators (1997) Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute MI. Circulation 96: 4239-4245
41. 41. Harris M-I, Eastman R-C (1998) Is there a glycemic threshold for mortality risk? Diabetes Care 21: 331-333
42. 42. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force (1994) Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15: 1300-1331
43. 43. Hanefeld M, Schmechel H, Schwanebeck U, Lindner J (1997) Predictors of coronary heart disease and death in NIDDM: The Diabetes Intervention Study experience. Diabetologia 40: S123-S124
44. 44. Pyörälä K, Pedersen T-R, Kjekshus J, Faergeman O, Olsson A, Throgeirsson G, for the Scandinavian Simvastatin Survival Study Group (1997) Lowering cholesterol levels improved the prognosis of diabetic patients with coronary heart disease. Diabetes Care 20: 614-620
45. 45. Sacks F-M, Pfeffer M-A, Moye L-A et al, for the physicians of the CARE study (1996) The effect of pravastatin on coronary events after MI in patients with average cholesterol levels. N Engl J Med 335: 1001-1009
46. 46. EUROASPIRE (1997) A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 18: 1569-1582
47. 47. Grundy S-M, Balady G-J, Criqui M-H et al (1997) Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from task force in risk reduction. Circulation 95: 2329-2331